Evan G. Dick
Corporate Officer/Principal bei CONTEXT THERAPEUTICS INC.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Martin Lehr | M | 40 | 9 Jahre | |
| Richard Berman | M | 81 | 3 Jahre | |
| Jennifer Stacey | F | 59 | 3 Jahre | |
| Philip Kantoff | M | 69 | 6 Jahre | |
| Linda West | F | 64 | 3 Jahre | |
| Jennifer Minai-Azary | F | 46 | 3 Jahre | |
| Alex Levit | M | 45 | 3 Jahre | |
| Felix Kim | M | - | 9 Jahre | |
| Christopher Beck | M | - | 2 Jahre | |
| Priya Marreddy | F | - | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Kamil Ali-Jackson | F | 65 |
Ception Therapeutics, Inc.
 Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA.
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 7 Jahre |
| Stephen Tullman | M | 58 |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | 5 Jahre |
| Craig Shular | M | 71 |
State University of New York at Buffalo
| 6 Jahre |
| Harold C. Smith | M | - |
State University of New York at Buffalo
| 5 Jahre |
| Glenn I. Henricksen | M | 64 |
State University of New York at Buffalo
| 6 Jahre |
| Doug Gessl | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Osagie Imasogie | M | 62 |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | 3 Jahre |
| Harry Patrick Barnum | M | - |
State University of New York at Buffalo
| 5 Jahre |
| Jeffrey S. Shaver | M | - |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA.
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Glenn Henrickson | M | - |
State University of New York at Buffalo
| 5 Jahre |
| Timothy J. Henkel | M | 65 |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA.
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| John H. Eldridge | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Howard A. Werman | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Kevin Centofanti | M | 64 |
State University of New York at Buffalo
| 6 Jahre |
| Sherwood Klein | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Stephen L. Giroux | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Suketu D. Desai | M | 59 |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | 3 Jahre |
| David A. Dooley | M | - |
State University of New York at Buffalo
| 1 Jahre |
| James P. Griffin | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Louis G. Henry | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Jamilus bin Mohamed Hussin | M | 80 |
State University of New York at Buffalo
| 1 Jahre |
| Ronald Lifton | M | 65 |
State University of New York at Buffalo
| 4 Jahre |
| Gary M. Stott | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Jeffrey Robert Paul | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Kim Wolin | F | 68 |
State University of New York at Buffalo
| 4 Jahre |
| James Nish | M | 65 |
State University of New York at Buffalo
| 4 Jahre |
| Tony Ogorek | M | - |
State University of New York at Buffalo
| 1 Jahre |
| Joel C. Schneider | M | 64 |
State University of New York at Buffalo
| 4 Jahre |
| Bob Schorr | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Siu Kin Fok | M | 70 |
State University of New York at Buffalo
| 4 Jahre |
| John Brodfuehrer | M | 66 |
State University of New York at Buffalo
| 4 Jahre |
| W. Anthony Sandonato | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Sunny Chukwudi Obidegwu | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Lewis I. Goldman | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Lisa Wittmer | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Jim Dowell | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Jim Badke | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Harvey L. Kaminski | M | - |
State University of New York at Buffalo
| 3 Jahre |
| John S. Malanowski | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Paul S. Molnar | M | 68 |
State University of New York at Buffalo
| 4 Jahre |
| Joe Frandina | M | - |
State University of New York at Buffalo
| 4 Jahre |
| David Oppenheimer | M | 67 |
State University of New York at Buffalo
| 4 Jahre |
| Martin Stogniew | M | 69 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Alan Cohen | M | 63 |
State University of New York at Buffalo
| 4 Jahre |
| Richard Rosenblum | M | 65 |
State University of New York at Buffalo
| 4 Jahre |
| Alan F. Joslyn | M | 65 |
State University of New York at Buffalo
| 4 Jahre |
| Todd N. Tipton | M | 67 |
State University of New York at Buffalo
| 4 Jahre |
| Gary Zieziula | M | 69 |
State University of New York at Buffalo
| 4 Jahre |
| Jordan Levy | M | 68 |
State University of New York at Buffalo
| 4 Jahre |
| Andrew B. Rosengard | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Robert Black | M | 65 |
State University of New York at Buffalo
| 4 Jahre |
| Francis J. Boggan | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Richard Gluck | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Curt Launer | M | 68 |
State University of New York at Buffalo
| 4 Jahre |
| Mark Sieczkarek | M | 69 |
State University of New York at Buffalo
| 4 Jahre |
| Frederick Muto | M | 70 |
State University of New York at Buffalo
| 4 Jahre |
| Jim Ferrare | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Andreas Polydoros | M | - |
State University of New York at Buffalo
| 1 Jahre |
| David M. Ascher | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Marc E. Shapiro | M | 67 |
State University of New York at Buffalo
| 4 Jahre |
| Jack Ross | M | 67 |
State University of New York at Buffalo
| 4 Jahre |
| Marc Tipermas | M | 76 |
State University of New York at Buffalo
| 2 Jahre |
| Timothy Lash | M | - |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | 4 Jahre |
| Patricia A. Cleveland | M | - |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | - |
| Kelly A. Copeland | F | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Peter Jerome Grogan | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Rod A. Ferguson | M | 67 |
State University of New York at Buffalo
| 3 Jahre |
| James M. Craig | M | 67 |
State University of New York at Buffalo
| 4 Jahre |
| Keith Blakely | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Martin J. Sumner | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Joseph I. Rader | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Jeffrey N. Meshulam | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Lewis Marks | M | 73 |
State University of New York at Buffalo
| 3 Jahre |
| Eric Lynn | M | - |
State University of New York at Buffalo
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 84 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Evan G. Dick
- Persönliches Netzwerk
